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Subtyping of Non-small Cell Lung Carcinoma
A Comparison of Small Biopsy and Cytology Specimens
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Maureen F. Zakowski, MD,* Raymond H. Thornton, MD,† Gregory J. Riely, MD, PhD,‡
and Natasha Rekhtman, MD, PhD*
Background: There is growing evidence that lung adenocarcinoma
and squamous cell carcinoma (SQCC) have distinct oncogenic
mutations and divergent therapeutic responses, which is driving the
heightened emphasis on accurate pathologic subtyping of non-small
cell lung carcinoma (NSCLC). The relative feasibility and accuracy
of NSCLC subtyping by small biopsy versus cytology is not well
established, particularly in current practice where immunohisto-
chemistry (IHC) is becoming routinely used to aid in this distinction.
Methods: Concurrent biopsy and cytology specimens obtained
during a single procedure and diagnosed as NSCLC during a 2-year
period (n  101) were reviewed. Concordance of diagnoses in the
two methods was assessed. Accuracy was determined based on
subsequent resection or autopsy diagnosis (n  21) or IHC for thyroid
transcription factor 1 and p63 on a subset of cases (n  43).
Results: The distribution of definitive versus favored versus unclas-
sified categories (reflecting the degree of diagnostic certainty) was
similar for biopsy (71% versus 23% versus 6%, respectively) and
cytology (69% versus 19% versus 12%, respectively), p  0.29.
When results from paired specimens were combined, the rate of
definitive diagnoses by at least one method was increased to 84%
and the unclassified rate was decreased to 4%. NSCLC subtype
concordance between biopsy and cytology was 93%. Kappa coeffi-
cient (95% confidence interval) for agreement between methods was
0.88 (0.60–0.89) for adenocarcinoma and 0.76 (0.63–0.89) for
SQCC. In pairs with discordant diagnoses (n  7) the correct tumor
type was identified with a similar frequency by biopsy (n  4) and
cytology (n  3). Factors contributing to mistyping were poor
differentiation, necrosis, low cellularity, and lack of supporting IHC.
All concordant diagnoses for which verification was available (n 
57) were correct. IHC was used more frequently to subtype NSCLC
in biopsy than cytology (32% versus 6%; p  0.0001).
Conclusions: Small biopsy and cytology achieve comparable rates
of definitive and accurate NSCLC subtyping, and the optimal results
are attained when the two modalities are considered jointly. The
lower requirement for IHC in cytology highlights the strength of
cytomorphology in NSCLC subtyping. Whenever clinically feasible,
obtaining parallel biopsy and cytology specimens is encouraged.
Key Words: Adenocarcinoma, Squamous cell carcinoma, Cytol-
ogy, Biopsy.
(J Thorac Oncol. 2011;6: 1849–1856)
The practice of subtyping of non-small cell lung carcinoma(NSCLC) as adenocarcinoma (ADC) versus squamous
cell carcinoma (SQCC) in pathologic specimens has under-
gone a major paradigm shift in recent years.1,2 Specifically,
subtyping of NSCLC is no longer viewed as unimportant
because of the discovery that several targetable molecular
alterations, particularly EGFR mutations3,4 and EML4-ALK
rearrangements,5 are largely restricted to ADC and because of
a non-squamous indication for bevacizumab and pemetrexed.6,7
Other important molecular differences between ADC and
SQCC are increasingly identified,8,9 suggesting that future
targeted therapies will be increasingly “histology specific.”
Selection of patients for appropriate molecular tests and
histology-based therapies necessitates accurate pathologic
distinction of ADC versus SQCC. As a result, a great em-
phasis is currently placed on accuracy of NSCLC subtyping
in pathologic specimens.
Because 70% of NSCLC are unresectable at presenta-
tion,10 treatment is often based on diagnoses from small
biopsy or cytology specimens. Until recently, NSCLC sub-
typing was based entirely on morphology with elective use of
mucin stains. However, the classic morphologic criteria for
differentiating ADC versus SQCC (glandular architecture and
intracellular mucin versus keratinization and intercellular
bridges, respectively) may be focal or subtle in small speci-
mens, particularly in poorly differentiated tumors. This ex-
plains the historically high rate of unclassified NSCLC des-
ignated as NSCLC-not otherwise specified (NOS) in both
small biopsy and cytology.11,12
An important recent development in NSCLC subtyping
is mounting evidence that immunohistochemistry (IHC) is a
powerful ancillary tool for the distinction of ADC and SQCC,
which substantially lowers the rate of unclassified and mis-
classified NSCLC and decreases the interobserver variability
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in small specimens.13–21 In particular, several recent studies
have shown that ADC and SQCC have virtually nonoverlap-
ping coexpression profiles of thyroid transcription factor 1
(TTF-1) and p63—the master transcriptional regulators in
glandular and squamous cell lineages, respectively.13,17,20–22
These robust markers are now increasingly incorporated into
routine clinical practice to aid in the diagnosis of morpho-
logically unclassifiable NSCLC (NSCLC-NOS). Recently,
our group performed a large cytology/resection correlation
study that showed that in a practice with routine utilization of
IHC, the rate of unclassified NSCLC is low (3%), and
accuracy of ADC versus SQCC subtyping is high—97%
overall and 100% for IHC-aided diagnoses,23 suggesting that
cytologic diagnoses in current practice are suitable for guid-
ing the new NSCLC subtype-based therapeutic decisions.
However, a direct comparison between the performance of
cytology versus small biopsy for NSCLC subtyping in the
current practice has not been performed.
In this study, we directly compared the rate with which
specific subtyping is achieved, the concordance and accuracy
of NSCLC diagnoses in cytology versus small biopsy speci-
mens obtained during a single procedure in the context of our
routine practice. As a means of verification of diagnostic
accuracy, we used not only resection/autopsy (as has been
done traditionally) but also IHC, based on the recent evidence
that IHC profiles are an extremely accurate means of deter-
mining tumor cell lineage in NSCLC. In addition, we com-
pared the frequency with which IHC is used to aid the
diagnosis in biopsy versus cytology in our routine practice.
PATIENTS AND METHODS
A review of the Memorial Sloan-Kettering Cancer
Center Department of Pathology database was conducted to
identify all concurrent small biopsy and cytology specimens
with a diagnosis of NSCLC during a 2-year period (January
1, 2006–January 1, 2008). The decision to obtain parallel
specimens (as opposed to a sole biopsy or cytology) was
made at the discretion of the individual interventional radi-
ologist or bronchoscopist. Selection was limited to cases in
which both biopsy and cytology were either diagnostic or
suspicious for malignancy, and NSCLC was reported by at
least one of the methods. Because the goal of the study was
to analyze NSCLC subtyping in actual clinical practice, we
recorded original diagnoses rendered during the initial case
review without modification. For determination of accuracy, the
diagnoses rendered by biopsy/cytology were compared with
subsequent resection (n  20) or autopsy (n  1) when avail-
able. In addition, IHC for TTF-1 (SPT24, NovoCastra, 1:50
dilution) and p63 (4A4, Dako, 1:700 dilution) was used as
another means of diagnosis verification. IHC was performed
either as part of initial work-up (n 38) or as part of this study
to resolve discordant diagnoses (n  5). Interpretation of TTF-
1/p63 immunoprofiles was based on the algorithm established in
recent studies.13,17,20,22 The morphologic features for all discor-
dant and unclassified cases were reviewed by two pathologists
with subspecialty expertise in cytopathology (N.R. and C.S.S.)
and thoracic pathology (N.R.).
The types of cytologic preparations included the fol-
lowing (according to standard specimen processing protocol
in our cytology laboratory): (1) air-dried smear stained with
Diff-Quik (used for immediate adequacy assessment), (2)
smear fixed in 95% ethanol and stained with hematoxylin and
eosin (H&E) or Papanicolaou stain, (3) ThinPrep monolayer
prepared from the needle rinse in CytoLyt fixative, and (4)
H&E-stained section from a paraffin-embedded cell block
prepared by centrifugation of CytoLyt fluid. No cell blocks
were available for cases with a very scant needle rinse, which
yielded no visible cell pellet after centrifugation. All fine-
needle aspirates (FNAs) were obtained with on-site adequacy
assessment by a cytotechnologist or pathologist. As part of
routine clinical practice during the study period, biopsy and
cytology specimens were reviewed independently by differ-
ent pathologists. Biopsy specimens were reviewed by pathol-
ogists with subspecialty expertise in thoracic pathology, and
the cytology specimens were reviewed by experienced staff
cytopathologists. A standard practice at our institution is for
cytology specimens to be reviewed and reports finalized a day
earlier than biopsy specimens due to a shorter processing time
of cytologic specimens, and therefore, in most cases, cyto-
logic diagnoses were rendered without the knowledge of
biopsy diagnosis. However, a correlative review may have
been performed at the discretion of individual pathologists,
and therefore, we cannot exclude that for a subset of cases,
diagnoses were rendered with the knowledge of the diagnosis
in the other specimen.
During the study period, the use of the terms “defini-
tive” versus “favored” versus “unclassified” reflected the
degree of diagnostic certainty as judged on case-by-case basis
by the individual pathologists. In general, definitive diagno-
ses (ADC or SQCC) were rendered when morphologic fea-
tures were diagnostic of a tumor type (such as obvious
glandular features or cytoplasmic mucin for ADC versus
keratinization for SQCC) or when IHC was interpreted as
diagnostic of a tumor type. The “favored” category was used
when morphology and IHC were interpreted as suggestive of
a tumor type but qualitatively or quantitatively insufficient for
definitive diagnosis. An alternative use of the “favored”
category has been recently proposed,24 but this study reflects
the use of this category in clinical practice during the study
period. The unclassified (NSCLC-NOS) category was used
for samples where tumor type could not be determined by
morphology, but cellularity was insufficient for IHC, or IHC
results were judged as equivocal. In addition, in some under-
classified cytology samples, IHC was intentionally withheld
because of the deferral of IHC to the concurrent biopsy to
avoid duplication of the workup. Because bronchoscopic
specimens usually include several cytologic specimens (bron-
chial brush, wash, lavage, and transbronchial FNA), the most
specific diagnosis reached by at least one of the methods was
recorded for the study purposes. For example, if a bronchial
brush was diagnosed as “ADC” and bronchial wash as
“NSCLC-NOS,” the overall diagnosis for cytology was re-
corded as “ADC.”
The significance of associations was assessed by two-
tailed Fisher’s exact test, with a p value of 0.05 considered
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statistically significant. Agreement was analyzed by calcula-
tion of Cohen’s kappa coefficient with the strength of asso-
ciation interpreted according to the following guidelines: very
good (0.81–1.00), good (0.61–0.80), moderate (0.40–0.60),
fair (0.20–0.40), and poor (0.20).25
This study was performed with the approval of the
Institutional Review Board of Memorial Sloan-Kettering
Cancer Center (New York, NY).
RESULTS
Specimen Characteristics
One hundred one patients had a concurrent cytology
and small biopsy specimens from the same diagnostic proce-
dures with diagnosis of NSCLC during the study period.
Specimens included concurrent transthoracic specimens—
transthoracic core biopsies paired with transthoracic FNAs
(n  60), and concurrent bronchoscopic specimens—trans-
bronchial biopsies paired with transbronchial FNAs (n  4)
and/or bronchial wash/brush/lavage (n  37). Seven trans-
thoracic core biopsies were paired with core touch prepara-
tions (core imprints); for the purposes of this study they were
analyzed as a single group with transthoracic FNAs. Average
follow-up was 14.6 months (range: 3 days–41 months). The
patient characteristics were male:female ratio, 1:1.9; average
age, 68 years; and age range, 37–91 years.
Comparison of Degree of Diagnostic Certainty
in Biopsy versus Cytology
The level of diagnostic certainty in NSCLC subtyping
consisted of three categories: definitive, favored, and unspec-
ified (NSCLC-NOS). As presented in Table 1, the distribution
of definitive versus favored versus unclassified categories
was similar for biopsy (71% versus 23% versus 6%, respec-
tively) and cytology (69% versus 19% versus 12%, respec-
tively), p  0.29. This distribution was similar for ADC and
SQCC in both methods. As presented in Table 2, a more
definitive diagnosis was made by biopsy in 17% of cases and
cytology in 13% of cases. By combining the results of the two
methods, the number of patients with unclassified diagnoses
was reduced to 4%, and the rate of definitive diagnosis by at
least one modality was increased to 84%. We did not find a
difference in the level of diagnostic certainty between various
cytology methods (transthoracic FNA versus transbronchial
FNA versus bronchial brush/wash/lavage) and between bi-
opsy methods (transthoracic biopsy versus transbronchial
biopsy) in this study.
Unclassified biopsy (n  6) and cytology (n  12)
specimens were distributed as follows: unclassified biopsy/
classified cytology (n  2), unclassified cytology/classified
biopsy (n  8), and both methods unclassified (n 4) (Table
1). In particular, review of unclassified biopsy/classified cy-
tology showed that in one instance, a tumor in the biopsy
sample was highly necrotic, whereas the cells were better
preserved in cytology, and in the second instance, a tumor
had poorly differentiated histology and IHC was noncontrib-
utory, whereas morphologic features in concurrent cytology
were diagnostic of a tumor type. In the unclassified cytology/
classified biopsy group, the majority (7/8) of biopsy diagno-
ses were aided by IHC. Four cases unclassified by both
methods were uniformly high-grade, poorly differentiated,
necrotic tumors. In two cases, the possibility of neuroendo-
crine carcinoma was considered, one case had basaloid mor-
phology and one case had pleomorphic/sarcomatoid morpho-
logic feature. In all cases, IHC results were equivocal.
Resection follow-up for these cases was not available.
Concordance and Accuracy of NSCLC
Subtyping in Biopsy versus Cytology
The concordance in the NSCLC subtypes between
biopsy and cytology was 93% (Table 3). Kappa coefficients
with 95% confidence intervals for the agreement of biopsy
and cytology diagnoses were 0.88 (0.60–0.89) for ADC, 0.76
(0.63–0.89) for SQCC, and 0.40 (0.10–0.69) for NSCLC-
NOS. NSCLC subtype was discordant in seven cases (7%).
For discordant diagnoses, subsequent resection (n  1),
autopsy (n  1), or additional IHC (n  5) revealed that the
TABLE 2. Correlation of Tumor Subtyping Categories for




Definitive 58 (57) 11 (11) 1 (1) 70
Favored 9 (9) 9 (9) 1 (1) 19
Unclassified 5 (5) 3 (3) 4 (4) 12
Total 72 23 6 101
TABLE 3. Correlation of Tumor Subtypes Diagnosed by




ADCa 51 (50) 5 (5) 2 (2) 58
SQCCa 2 (2) 29 (28) 0 31
Unclassified 4 (4) 4 (4) 4 (4) 12
Total 57 38 6 101
a Includes both definitive and favored diagnoses.
ADC, adenocarcinoma; SQCC, squamous cell carcinoma.
TABLE 1. Distribution of Tumor Subtyping Categories
Reflecting the Degree of Diagnostic Certainty for Biopsy
versus Cytology
Biopsy, N (%) Cytology, N (%)
Total ADCa SQCCa Total ADCa SQCCa
Definitive 72 (71) 44 (77) 28 (74) 70 (69) 47 (81) 23 (74)
Favored 23 (23) 13 (23) 10 (26) 19 (19) 11 (19) 8 (26)
Unclassified 6 (6) — — 12 (12) — —
Total 101 57 38 101 58 31
a Original diagnosis rendered on biopsy or cytology.
ADC, adenocarcinoma; SQCC, squamous cell carcinoma.
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correct diagnosis was rendered with a similar frequency by
biopsy (n  4) and cytology (n  3) (Table 4). Misclassified
cytologic specimens included an even number of SQCC (n 
2) and ADC (n  2), whereas misclassified biopsies were all
ADC morphologically mimicking SQCC due to solid growth
pattern and abundant pink cytoplasm (n  3). The morpho-
logic pitfalls are illustrated in Figure 1. Overall, all misclas-
sified case were scant specimens of poorly differentiated
and/or necrotic tumors classified in the absence of IHC. All
biopsy and cytology specimens with concordant diagnoses
for which resection or IHC verification was available (n 
53) were correct.
Utilization of IHC in Routine Practice
As summarized in Table 5, utilization of IHC to aid in
the diagnosis of ADC and SQCC was significantly higher in
biopsy than cytology (32% versus 6%, p  0.0001). Diag-
nosis of ADC was more commonly aided by IHC in biopsy
than cytology (21% versus 6%, p  0.003), as was the
diagnosis of SQCC (11% versus 0, p 0.0015). The majority
of IHC-aided diagnoses were classified as “definitive” in both
biopsy (66%) and cytology (83%), and the rest were classi-
fied as “favored.”
For paired specimens where the diagnosis of SQCC
required IHC in biopsy but not cytology, definite evidence of
keratinization was evident in Papanicolaou-stained cytologi-
cal preparations but was inapparent on H&E-stained biopsies
(Figures 2A–C). Similarly, clear evidence of glandular dif-
ferentiation (polarized cells with a flat luminal edge and/or
acinar structures) was readily identifiable in cytology speci-
mens in which concurrent biopsy was indefinite for the tumor
type and required IHC for diagnosis (Figures 2D–F).
DISCUSSION
The main finding of this study is that in our institutional
experience paired small biopsy and cytology specimens
achieve a comparable certainty and accuracy in NSCLC
subtyping, and optimal results are obtained when the findings
from both methods are combined. In particular, results from
combined methods maximize the number of definitive diag-
noses by at least one modality and decrease the rate of
unclassified diagnoses (NSCLC-NOS).
The number of prior studies which have directly com-
pared the efficacy of NSCLC subtyping in paired small
biopsy versus cytology specimens is limited, and none have
been performed in a practice where IHC is routinely used to
subtype morphologically challenging cases. Similar to the
findings of this study, prior studies found that the feasibility
and accuracy of subtyping of malignant tumors overall was
comparable in paired biopsy and cytology specimens.26–28 Of
note, in prior studies, the ability to determine specific diag-
noses for benign tumors and mass-forming lesions (such as
organizing pneumonia) was superior for biopsy,26,27 which
remains the main advantage of biopsy over cytology. The
reported rate of unclassified specimens and accuracy of
NSCLC subtyping in unpaired small specimens varies signif-
icantly among prior studies,11,12,29,30 with unclassified
NSCLC rate of more than 30% reported in some studies.30
This is in stark contrast with the low rate of unclassified
NSCLC by combined (4%) and individual methods in this
series and recent cytology23 and small biopsy31 studies from
our institution. The low unclassified rate (and high concor-
dance and accuracy) of biopsy and cytology in this study is
attributable at least in part to routine utilization of IHC for
subtyping of difficult cases. This approach is becoming in-
corporated in routine practice in recent years and is recom-
mended in the recent IASLC/ATS/ERS ADC classification
proposal.24 In addition to the role of IHC, the high rates of
NSCLC subtyping in this series may be partially reflective of
practice in a subspecialized referral cancer center.
A key observation in this study is that morphologic
evidence of differentiation as ADC or SQCC is frequently
more apparent in cytologic specimens than in small biopsies.
This is demonstrated by the significantly lower need for IHC
to identify a tumor type in cytology compared with biopsy
(6% versus 31%, respectively) despite a similar degree of
certainty and accuracy of NSCLC subtyping by these meth-
ods. The main advantage of cytologic preparations in NSCLC
subtyping is that the Papanicolaou stain (a routine stain in
cytology) specifically highlights keratinizing cells, whereas
TABLE 4. Review of Cases with Discrepant Biopsy and Cytology Diagnoses







1 TTNA TTB Favor SQCC Favor ADC ADC Resection Bx Poor differentiation, necrosis, low cellularity
2a BBR TBB Favor SQCC Favor ADC ADC Autopsy Bx Poor differentiation
3 BBR TBB Favor ADC SQCC SQCC IHC Bx Poor differentiation
4b BW TBB ADC SQCC SQCC IHC Bx Poor differentiation
5c BW TBB ADC Favor SQCC ADC IHC Cyto Poor differentiation
6 BW TBB ADC Favor SQCC ADC IHC Cyto Poor differentiation, necrosis




d All incorrect subtypes were assigned in the absence of confirmatory immunohistochemistry.
ADC, adenocarcinoma; BBR, bronchial brushing; BW, bronchial washing; Bx, biopsy; Cyto, cytology; Dx, diagnosis; SQCC, squamous cell carcinoma; TBB, transbronchial
biopsy; TTB, transthoracic biopsy; TTNA, transthoracic fine needle aspiration.
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H&E (a routine stain in histology) does not. This accounts for
greater ability of routine cytology to identify squamous dif-
ferentiation without the aid of IHC. Another advantage of
cytology is that the three-dimensional cell arrangements of
ADC may be better visualized in cytology than histology.
Finally, cytology lacks formalin-fixation artifact and has less
crush artifact compared with small biopsy, which allows for
greater resolution of nuclear and cytoplasmic detail. This
latter factor accounts for a well-known advantage of cytology
over small biopsy in the diagnosis of small cell lung carci-
noma.32,33 Our data support the conclusion that cytology
offers a similar advantage in the subtyping of NSCLC.
A novel approach used in this study was to use IHC (in
addition to final diagnosis in subsequent resection or autopsy)
as a means of verifying the accuracy of the small specimen
diagnoses. Several recent studies have shown that ADC and
SQCC have distinct profiles of TTF-1 and p63 expres-
sion,13,17,20–22 and this can be used to aid in the diagnosis of
morphologically challenging cases. The recently developed
IHC algorithm is becoming increasingly incorporated into
clinical practice (as discussed earlier) and provides an alter-
native gold standard for measuring the accuracy of small
specimens. The validity of this approach is supported by
recent studies showing that tumor type identified by IHC in
preoperative specimens predicts with excellent accuracy the
resection diagnosis of ADC versus SQCC.13,20,23
The study design, which included specimens obtained
during a single procedure, was chosen to allow the most
direct comparison between cytology and biopsy specimens;
however, this approach has several limitations. The main
disadvantage of this approach is that paired specimens may
not be entirely representative of the individual, isolated per-
formance of either method. For example, the total number of
FNA passes performed by an interventional radiologist may
be reduced if a core biopsy is obtained concurrently, resulting
in a less cellular cytology specimen. Conversely, FNA may
be more likely to be obtained in cases where a core biopsy is
judged to be suboptimal, particularly if friable or minute. The
second limitation is that for some paired specimens patholo-
gists may elect to render a more generic diagnosis (such as
NSCLC-NOS) in cytology, and defer the IHC work-up and
further classification to a biopsy. Therefore, the relative rate
of IHC utilization and the rate of unclassified specimens in
this study may not reflect a full potential of cytology for
NSCLC subtyping, which is more accurately reflected in a
study where cytology is the only diagnostic modality.23 The
third limitation of the study is that verification of diagnosis
(in the form of resection, autopsy or IHC) was not available
for nearly half of the patients. As a result, the primary
conclusion from this study is the high level of concordance in
the diagnoses, whereas the conclusion for comparable accu-
racy is based on only a subset of cases.
In addition to tumor subtyping, another important
consideration in the method comparison is diagnostic yield
(i.e., the rate of successful sampling of a mass lesion).
Because in this study only cases that were diagnostic by
both modalities were selected, the comparative diagnostic
FIGURE 1. Examples of rare cases with discrepant adeno-
carcinoma (ADC) versus squamous cell carcinoma (SQCC)
diagnoses in biopsy and cytology. A and B, ADC identified as
SQCC by cytology with correct diagnosis of ADC in concur-
rent biopsy. Cytology (A) shows carcinoma cells with dense
blue cytoplasm mimicking SQCC. Concurrent biopsy (B)
shows poorly differentiated non-small cell carcinoma, which
was diffusely positive for TTF-1 (not shown) supporting ADC.
C and D, SQCC identified as ADC by cytology with correct
diagnosis of SQCC in concurrent biopsy: Cytology (C) shows
three-dimensional clusters of nonkeratinizing cells with
prominent nucleoli, closely mimicking ADC. (D) Poorly dif-
ferentiated carcinoma with focal squamous whorls diagnos-
tic of SQCC is seen on the corresponding biopsy. E and F,
ADC identified as SQCC by biopsy with correct diagnosis of
ADC in concurrent cytology: Polarized (eccentric) nuclei and
granular cytoplasm support ADC in cytology (E). Tumor cells
in concurrent biopsy (F) have abundant pink cytoplasm and
sharp cell borders mimicking SQCC. This tumor was found
to be diffusely positive for TTF-1 and negative for p63, sup-
porting ADC (not shown). A, C, and E, Papanicolaou stain,
400. B, D, and F, H&E stain, 400.
TABLE 5. Utilization of Immunohistochemistry to Distinguish
of Adenocarcinoma and Squamous Cell Carcinoma in




(n  101) p
ADC diagnosis aided by IHC 21 (21) 6 (6) 0.003
SQCC diagnosis aided by IHC 11 (11) 0 0.0015
Total number of ADC and
SQCC diagnoses aided by IHC
32 (32) 6 (6) 0.0001
IHC, immunohistochemistry; ADC, adenocarcinoma; SQCC, squamous cell
carcinoma.
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yield of biopsy versus cytology cannot be addressed.
However, prior studies show that diagnostic yield is com-
parable for transthoracic biopsy and FNA,26,27,34–36
whereas results vary for different bronchoscopic meth-
ods.28,36 Importantly, several studies show significant im-
provement in the diagnostic yield by combining biopsy and
cytology specimens in a single bronchoscopic28,37–39 or
transthoracic26,27,40 procedure. It is fairly standard in bron-
choscopic procedures to obtain cytological preparations
concurrently with a biopsy, whereas for transthoracic ap-
proaches, the material obtained is more variable.41 When a
concurrent FNA is obtained with a transthoracic core
biopsy, it is a common view that the utility of cytology is
limited to on-site adequacy assessment to confirm the
successful targeting of a lesion, but that cytology does not
have an important role in reaching the final diagnosis. In
contrast, we show a distinct value added by cytologic
specimens, in that in a subset of cases a more specific and
accurate diagnosis is achieved in cytology. Together with
prior studies showing the advantage of paired specimens
for maximizing the overall diagnostic yield, an attempt
should be made to obtain paired specimens whenever
clinically possible.
Another essential consideration for small specimens
in the age of targeted therapies is suitability for molecular
testing. Although this question was not addressed in the
current study, several prior studies have shown that cytol-
ogy specimens, particularly FNAs are highly suitable for
EGFR (and KRAS) mutation analysis.16,23,42–45 Recent
studies from our institution suggest that overall small
biopsies and FNAs have a comparable rate of yielding
sufficient material for molecular testing,23,46,47 although
further studies are needed to directly compare specific
specimen types. In particular, when deciding on a method
of tissue sampling, an important consideration is that
standard molecular studies and IHC generally require cel-
lular paraffin-embedded material (formalin-fixed paraffin-
embedded tissue for biopsy and cell block for cytology).
Although FNAs typically yield enough material for a cell
block, other cytologic specimens (sputum, bronchial
brush/wash/lavage) are usually insufficient for a cell block
and cannot be used for routine IHC or molecular studies. In
particular, core touch preparations (core imprints),48 which
are currently used at some institutions, including ours, for
immediate on-site assessment of adequacy of a core bi-
opsy, should not be regarded as an FNA-equivalent as they
do not yield a cell block and cannot be used for routine
ancillary studies. For both biopsies and FNAs, obtaining
tissue in excess of what traditionally has been sufficient for
a minimal morphologic diagnosis of non-small cell carci-
noma versus small cell carcinoma (which may require only
a few tumor cells) is now necessary to ensure that cellu-
larity is sufficient for potential IHC or molecular studies.
This can be achieved by performing additional FNA passes
and maximizing the amount of material in the needle-rinse
fluid, which is used as a source of a cell block, or by
obtaining an extra biopsy, if clinically feasible. Close
interdisciplinary communication is encouraged to ensure
that the specimens are providing sufficient material for the
optimal diagnosis and predictive marker testing.
In summary, in our routine practice, small biopsy and
cytology specimens achieve comparable specificity and ac-
curacy of NSCLC subtyping, and optimal results are obtained
when the findings from both modalities are combined. We
therefore recommend obtaining concurrent biopsy and cytol-
ogy samples, whenever clinically feasible, and correlating the
results from both methods to ensure the greatest diagnostic
accuracy.
FIGURE 2. Definitive morphologic evidence of squamous or glandular differentiation is frequently more apparent in cytologic
preparation than biopsies. Cytology specimen (A) shows definitive keratinization (dense red or orange cytoplasm) diagnostic
of squamous cell carcinoma. In contrast, keratinization is inapparent in concurrent biopsy (B) which required immunohisto-
chemistry (IHC, positive p63; C) for the diagnosis. IHC for TTF-1 was negative (not shown). Cytology specimen (D) shows ec-
centric nuclei with flat luminal edge (arrow) diagnostic of adenocarcinoma. In contrast, morphologic differentiation is inappar-
ent in concurrent core biopsy (E) and required IHC (positive TTF-1; F) for the diagnosis. A and D, Papanicolaou stain, 400. B
and E, H&E stain, 400. C and F: Immunohistochemistry for p63 and TTF-1, respectively, 400.
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